The cutoff for estrogen and progesterone receptor expression in
endometrial cancer revisited: a European Network for
Individualized Treatment of Endometrial Cancer collaboration
study

J 2021

The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

WEELDEN, Willem Janvan, Casper REIJNEN, Heidi V.N. KÜSTERS-VANDEVELDE, Johan BULTEN, Peter BULT et. al.

Basic information

Original name

The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

Authors

WEELDEN, Willem Janvan (guarantor), Casper REIJNEN, Heidi V.N. KÜSTERS-VANDEVELDE, Johan BULTEN, Peter BULT, Samuel LEUNG, Nicole C.M. VISSER, Maria SANTACANA, Peter BRONSERT, Marc HIRSCHFELD, Eva COLAS, Antonio GIL-MORENO, Armando REQUES, Gemma MANCEBO, Jutta HUVILA, Martin KOSKAS, Vít WEINBERGER (203 Czech Republic, belonging to the institution), Markéta BEDNAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Marc P.L.M. SNIJDERS, Xavier MATIAS-GUIU and Frédéric AMANT

Edition

Human Pathology, Philadelphia, Elseveir, 2021, 0046-8177

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.526

RIV identification code

RIV/00216224:14110/21:00121057

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.humpath.2020.12.003

UT WoS

000632654300007

Keywords in English

Endometrial cancer; Estrogen receptor; Progesterone receptor; Cutoff; Prognostic biomarker

Abstract

V originále

There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1–2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1–30%. Sensitivity was highest for the cutoff values of 80–90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0–10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9–83.3%); 20–80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0–93.9%); and 90–100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8–100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0–10%), intermediate-risk (20–80%), and low-risk (90–100%) group.

Citovat

WEELDEN, Willem Janvan, Casper REIJNEN, Heidi V.N. KÜSTERS-VANDEVELDE, Johan BULTEN, Peter BULT, Samuel LEUNG, Nicole C.M. VISSER, Maria SANTACANA, Peter BRONSERT, Marc HIRSCHFELD, Eva COLAS, Antonio GIL-MORENO, Armando REQUES, Gemma MANCEBO, Jutta HUVILA, Martin KOSKAS, Vít WEINBERGER, Markéta BEDNAŘÍKOVÁ, Jitka HAUSNEROVÁ, Marc P.L.M. SNIJDERS, Xavier MATIAS-GUIU and Frédéric AMANT. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology. Philadelphia: Elseveir, 2021, vol. 109, March 2021, p. 80-91. ISSN 0046-8177. Available from: https://dx.doi.org/10.1016/j.humpath.2020.12.003.

@article{1735416,
   author = {Weelden, Willem Janvan and Reijnen, Casper and KüstersandVandevelde, Heidi V.N. and Bulten, Johan and Bult, Peter and Leung, Samuel and Visser, Nicole C.M. and Santacana, Maria and Bronsert, Peter and Hirschfeld, Marc and Colas, Eva and GilandMoreno, Antonio and Reques, Armando and Mancebo, Gemma and Huvila, Jutta and Koskas, Martin and Weinberger, Vít and Bednaříková, Markéta and Hausnerová, Jitka and Snijders, Marc P.L.M. and MatiasandGuiu, Xavier and Amant, Frédéric},
   article_location = {Philadelphia},
   article_number = {March 2021},
   doi = {http://dx.doi.org/10.1016/j.humpath.2020.12.003},
   keywords = {Endometrial cancer; Estrogen receptor; Progesterone receptor; Cutoff; Prognostic biomarker},
   language = {eng},
   issn = {0046-8177},
   journal = {Human Pathology},
   title = {The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study},
   url = {https://www.sciencedirect.com/science/article/pii/S0046817720302550?via%3Dihub},
   volume = {109},
   year = {2021}
}

TY  - JOUR
ID  - 1735416
AU  - Weelden, Willem Janvan - Reijnen, Casper - Küsters-Vandevelde, Heidi V.N. - Bulten, Johan - Bult, Peter - Leung, Samuel - Visser, Nicole C.M. - Santacana, Maria - Bronsert, Peter - Hirschfeld, Marc - Colas, Eva - Gil-Moreno, Antonio - Reques, Armando - Mancebo, Gemma - Huvila, Jutta - Koskas, Martin - Weinberger, Vít - Bednaříková, Markéta - Hausnerová, Jitka - Snijders, Marc P.L.M. - Matias-Guiu, Xavier - Amant, Frédéric
PY  - 2021
TI  - The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
JF  - Human Pathology
VL  - 109
IS  - March 2021
SP  - 80-91
EP  - 80-91
PB  - Elseveir
SN  - 00468177
KW  - Endometrial cancer
KW  - Estrogen receptor
KW  - Progesterone receptor
KW  - Cutoff
KW  - Prognostic biomarker
UR  - https://www.sciencedirect.com/science/article/pii/S0046817720302550?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0046817720302550?via%3Dihub
N2  - There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1–2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1–30%. Sensitivity was highest for the cutoff values of 80–90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0–10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9–83.3%); 20–80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0–93.9%); and 90–100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8–100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0–10%), intermediate-risk (20–80%), and low-risk (90–100%) group.
ER  -

WEELDEN, Willem Janvan, Casper REIJNEN, Heidi V.N. KÜSTERS-VANDEVELDE, Johan BULTEN, Peter BULT, Samuel LEUNG, Nicole C.M. VISSER, Maria SANTACANA, Peter BRONSERT, Marc HIRSCHFELD, Eva COLAS, Antonio GIL-MORENO, Armando REQUES, Gemma MANCEBO, Jutta HUVILA, Martin KOSKAS, Vít WEINBERGER, Markéta BEDNAŘÍKOVÁ, Jitka HAUSNEROVÁ, Marc P.L.M. SNIJDERS, Xavier MATIAS-GUIU and Frédéric AMANT. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. \textit{Human Pathology}. Philadelphia: Elseveir, 2021, vol.~109, March 2021, p.~80-91. ISSN~0046-8177. Available from: https://dx.doi.org/10.1016/j.humpath.2020.12.003.

Detailed Information on Publication Record